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Summary
Hepatitis C virus (HCV)- infected patients are at risk of developing hepatocellular car-
cinoma (HCC). Individuals at heightened risk could be targeted by intensive follow- up 
surveillance. We have conducted a systematic review of the literature to identify 
host genetic predisposition to HCC in HCV- infected patients. A comprehensive 
search of Medline and Embase databases was performed, and the strength of evi-
dence of associations for each gene on development of HCC was evaluated. We iden-
tified 166 relevant studies, relating to 137 different genes, or combinations thereof. 
Seventeen genes were classified as having “good” evidence of an association, a sig-
nificant association was observed for 37 genes but this finding had not yet been 
replicated, 56 genes had mixed or limited evidence of an association, and 27 genes 
showed no association. IFNL3/4, TNF-α and PNPLA3 genes had the most evidence of 
an association. There was, however, considerable heterogeneity in study design and 
data quality. In conclusion, we identified a number of genes with evidence of associa-
tion with HCC, but also a need for more standardized approaches to address this 
clinically critical question. It is important to consider the underlying mechanism of 
these relationships and which are confounded by the presence of other HCC risk fac-
tors and response to therapy. We also identified many genes where the evidence of 
association is contradictory or requires replication, as well as a number where asso-
ciations have been studied but no evidence found. These findings should help to di-
rect future studies on host genetic predisposition to HCC in HCV- infected patients.
K E Y W O R D S
genetic predisposition, hepatitis C virus, hepatocellular carcinoma, risk stratification
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1  | INTRODUC TION
Chronic hepatitis C virus (HCV) infection is one of the aetiolog-
ical factors underlying the development of hepatocellular car-
cinoma (HCC), a commonly observed tumour whose incidence 
is  increasing.1 Typically, HCC develops after sustained liver 
damage, where disease usually progresses from mild to severe 
 fibrosis, then cirrhosis and eventually to HCC. Only a propor-
tion of patients with cirrhosis will develop HCC (1%- 7% per 
year).2
The question of which HCV- infected patients are at risk of de-
veloping HCC is an important one, especially in the era of effec-
tive direct- acting antiviral (DAA) oral treatments.3 Even if most 
patients are likely to become free of HCV through DAA therapy, it 
remains important to assess which patients need continuing sur-
veillance for early detection and treatment of HCC and other liver 
disease. While there are many risk factors for HCC, including al-
cohol use, viral hepatitis and metabolic diseases, host genetics are 
likely to play a crucial role. Knowledge of host genetics therefore 
could add discriminatory value to risk prediction tools, allowing 
better stratification and personalized assessment of optimal long- 
term management, thereby increasing the efficacy of surveillance 
programmes.
This systematic literature review identified publications which 
examine the association between specific human genes/single nu-
cleotide polymorphisms (SNPs) and the occurrence of HCC. We have 
aggregated and graded the evidence for each studied gene according 
to the strength of evidence for an association with HCC. As cirrhosis 
itself is a risk factor for HCC development, we also included reports 
of the association between host genetics and cirrhosis and fibrosis 
progression. Our aim in undertaking this task was purely utilitarian, 
that is with a view to developing appropriate genetic testing to aid 
in patient stratification and clinical management—as opposed to 
a mechanistic approach aiming to shed light on the molecular pro-
cesses underlying the pathogenesis of HCC. We identify a large num-
ber of human genes which have been studied in relation to HCV and 
HCC, and classify these genes according to the strength of evidence 
of an association.
2  | METHODS
2.1 | Search strategy
We conducted a comprehensive literature search in Ovid MEDLINE 
and Embase databases for relevant papers, using the search strategy 
listed in Appendix S4, divided into the following categories: hepato-
cellular carcinoma, hepatitis C, genetics and risk/associations. The 
search strategy was developed by two researchers and checked by 
another independently.
To refine the search, review papers were excluded and stud-
ies were limited to the English language. Studies were limited to 
humans.
2.2 | Study selection
Studies were included if they:
• Included patients infected with HCV,
• Evaluated associations between germline polymorphisms and 
HCC, cirrhosis or fibrosis,
• Had a case-control design or
• Were a relevant meta-analysis.
Study eligibility was assessed by two independent reviewers, 
firstly at the title level, then through abstract assessment and then by 
assessing the full texts. Reviewer discrepancies were resolved with the 
assistance of a third reviewer.
2.3 | Data extraction
We extracted odds or hazard ratios from the selected papers, 
along with pertinent details of the study, including SNP refer-
ence number where available (rs#), sample size, data on adjust-
ment or matching, the outcome studied and the comparison/
control group used. Where multiple genes and/or SNPs were ana-
lysed within the same study, we extracted data for each gene/
SNP. Similarly, if a study used multiple outcomes (ie HCC, cirrho-
sis or fibrosis), we extracted results for each of these. In cases 
where there were multiple comparison groups (eg HCC patients 
being compared with both HCV- infected patients and healthy con-
trols), we extracted data for the HCV- infected comparison. Full 
data tables are available in Appendix S3 (here: https://figshare.
com/s/2ffc9030826df2fe150e).
2.4 | Classification of studies—strength of evidence
In order to provide an indication of the strength of evidence 
for each gene, all studies relating to each gene were collated 
together and each gene was classified into one of four catego-
ries. These categories were determined a priori and broadly were 
based upon genes having had a significant association which was 
replicated in a separate study and an absence of substantive 
disagreement.
Criteria for strength of evidence:
• Genes/SNPs with strong evidence
○ ≥2 studies with a significant association (as defined by each 
study) with HCC, and
○ Absence of substantial disagreement/negative studies or
○ Positive meta-analysis;
• Studies in need of replication
○ Only one HCC study performed, but with a significant asso-
ciation found;
• Genes/SNPs with some/mixed evidence
○ Multiple studies carried out but with disagreement or
○ Positive studies, but only in cirrhosis or fibrosis, not HCC;
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• Genes/SNPs with no evidence
○ Only negative studies or
○ Negative meta-analysis (regardless of other studies).
3  | RESULTS
3.1 | Identified study characteristics
The search criteria identified 1668 unique studies for review 
(Figure 1). After review, 166 studies investigating the association of 
host genetic polymorphisms with fibrosis progression, cirrhosis or 
HCC development in chronic HCV- infected patients were selected as 
being relevant. One hundred and fifty- six of these were original re-
search articles, of which 150 were candidate gene studies, and 6 were 
genomewide association studies (GWAS). The remaining studies (10) 
were meta- analyses. HCC was used as an outcome in 90 studies, 
while 45 used cirrhosis and 41 used fibrosis (some studies had mul-
tiple outcomes). The 166 selected papers are listed in Appendix S2.
There was considerable heterogeneity between studies in a 
number of parameters: various comparison groups were used, the 
most common being HCV- infected patients without HCC, cirrho-
sis or fibrosis (74.7% of all studies). These comparison groups dif-
fered substantially between studies using cirrhosis/fibrosis as an 
outcome—which almost all compared with HCV- infected patients 
(92.1%)—and HCC as an outcome, where healthy subjects (21.1%) 
and HCV cirrhosis patients (10.0%) were more frequently used. 
The median sample size in the identified research studies was 294 
patients (IQR 161- 431, range 30- 6880). Studies also varied in the 
extent to which patients and comparators were matched, from no 
matching at all through to matching for age, gender, alcohol intake, 
source of infection and duration of infection.
A total of 133 individual genes were featured within the iden-
tified studies, as well as 4 different gene combinations, where the 
combined effect of polymorphisms within two or more genes, were 
considered. These studies may have investigated a single gene or 
multiple genes or in some cases multiple SNPs within the same gene.
Tables 1-4 contain summarized details of all studied genes, cat-
egorized into the 4 levels of evidence described in the methods. A 
large amount of additional detail, including results for individual 
studies, hazard/odds ratios, significance, sample size and inclusion/
exclusion criteria, can be found in Appendix S3 (also available here: 
https://figshare.com/s/2ffc9030826df2fe150e), which contains 
corresponding Tables (1-4) with all the detail extracted from each 
study, for each gene. Additional detail is provided in the text below 
within which we have only cited examples of papers relating to HCC, 
and only for genes with strong evidence.
3.2 | Genes/SNPs with strong evidence
We identified 17 genes with strong evidence of an association with 
HCC in HCV- infected patients (Table 1 and Appendix S3 available 
at https://figshare.com/s/2ffc9030826df2fe150e), although even 
within this group the level of evidence varied substantially. The 
number of HCC studies for each gene ranged from 2 to 7 (median 
3), while for 8 of these genes, there were additional studies which 
found an association with cirrhosis or fibrosis. A total of 42 original 
studies involving HCC as an outcome made up the evidence base for 
these genes. An additional 25 studies involved cirrhosis or fibrosis 
as an outcome. A large majority of these studies used HCV- infected 
patients (with or without cirrhosis) as a control group, although some 
(which we identify below) used healthy subjects as controls. Table 5 
indicates which studies used HCV- infected patients with cirrhosis 
but without HCC as their control group. Matching and adjustment 
were highly variable between studies, and this is best explored 
using the data in Appendix S3. The total number of patients stud-
ied for each gene ranged from 189 to 15 152 (median 1223), while 
F IGURE ­1 Results of the search 
strategy
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the median sample size for each individual study (excluding meta- 
analyses) was 277 (range 30- 6880).
3.2.1 | ALDH2
The ALDH2 gene encodes the mitochondrial aldehyde dehydroge-
nase enzyme. Two reports studied ALDH2, both of which used HCC 
as the outcome and were candidate gene studies, comprising a total 
of 638 patients. Kato et al4 found a significant association in 170 pa-
tients, with controls being age- and gender- matched HCV- infected 
cirrhosis patients. Alcohol was not adjusted for in this analysis but 
was in the second paper5 where a significant association was de-
termined in 468 patients, where the comparison group was HCV- 
infected patients without cirrhosis.
3.2.2 | CAT
The antioxidant enzyme catalase is encoded by the CAT gene. A total 
of 482 patients were studied across two different studies, both of 
which found an association with the SNP rs1001179.6,7 There was a 
large disparity in odds ratio between these two studies (13.6 and 1.74), 
which may be explained in part by the different comparison groups 
used (noncirrhotic and cirrhotic HCV- infected patients, respectively).
3.2.3 | EGF
Three original studies were identified investigating the rs4444903 
SNP of the EGF gene, two studying HCC8,9 (578 patients in total) 
and one studying fibrosis, with a variety of comparison groups 
(including HCV- infected and HCV- related cirrhosis patients). The 
EGF gene encodes epidermal growth factor. All studies found a 
significant association with the outcome, although for one,9 the 
association was only significant for the A/A to A/G comparison 
(and not for A/A to G/G). Additionally, a meta- analysis10 describing 
comparisons between HCC patients and both patients with liver 
disease and healthy controls found a significant overall effect.
3.2.4 | GSTM1
A deletion of the GSTM1 gene—which encodes the glutathione 
S- transferase mu 1 protein—was associated with HCC in two stud-
ies.11,12 A relatively small total number of patients (n = 189) were 
included across these two studies, and the applicability to HCV is 
potentially questionable, given that only subsets of the patients in 
both studies were HCV- infected, with the remaining patients having 
cirrhosis caused by other aetiologies.
3.2.5 | GSTT1
GSTT1 (encoding glutathione S- transferase theta 1) is related to 
GSTM1, and indeed, the same studies11,12 (and same 189 patients) 
which identified an association with the GSTM1 gene deletion 
also found a similar association between GSTT1 gene deletion 
and HCC. The same caveats regarding applicability to HCV also 
apply.
3.2.6 | HLA
While not a single gene, the HLA gene complex (which encodes the 
major histocompatibility complex) has been widely studied with re-
spect to its association with HCC, cirrhosis and fibrosis. Three of the 
HLA genes HLA-Bw4,13 HLA-B1814 and HLA-DR1114 were reported 
to be associated with HCC in two studies by the same group, which 
investigated a total of 293 patients. An additional four studies found 
associations between various HLA genes/alleles and cirrhosis, in-
cluding two candidate gene studies and a GWAS.
3.2.7 | HLA-­Bw4+KIR3DS1
In addition to the evidence of HLA genes associated with HCC 
alone, three studies13,15,16 (with a total of 776 patients) identified 
the pairing of HLA-Bw4 and KIR3DS1 (which encodes a transmem-
brane glycoprotein expressed by natural killer cells) in combination 
as being associated with HCC.
3.2.8 | HSPA1B
Two studies (with a total of 666 patients) identified an association 
between HSPA1B—which encodes a heat- shock protein—and HCC in 
HCV- infected patients.17,18 One study of 366 patients18 used a com-
parison group of HCV- infected patients, while the other17 with 300 
patients used healthy controls and only 44 patients in total within 
this study were HCV- positive.
3.2.9 | IFNL3/IFNL4
The IFNL3 (previously IL-28B) and IFNL4 genes encode the interferon 
lambda 3 and lambda 4 cytokines, respectively. More studies were 
identified for IFNL3/IFNL4 than any other gene, with seven original 
studies (with a total of 3,154 patients) and three meta- analyses using 
HCC as an outcome and six using cirrhosis or fibrosis. Two different 
SNPs were investigated—rs8099917 in 4 of the original studies and 
rs12979860 in 4 of them. These SNPs are in linkage disequilibrium 
meaning it would not be surprising if their associations with HCC 
are similar. For rs8099917, three of the studies found a significant 
association with HCC,19,20 while one did not.21 However, this is not 
unexpected due to different patterns of correlation between SNPs 
in patients from different ethnic origin. For rs12979860, two studies 
found a significant association with HCC22,23 and two did not.24,25 
Additionally, one study found a significant association with cirrho-
sis, although most studies using cirrhosis or fibrosis as an outcome 
did not find an association. Four of the studies were meta- analyses, 
with three of these focusing on rs12979860 and HCC26-28 and one 
focusing on fibrosis. Of these, two meta- analyses found a positive 
association between rs12979860 and HCC26,27 and one found an as-
sociation between fibrosis and rs12979860.
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3.2.10 | IL-­1b
The IL-1b gene encodes the cytokine interleukin- 1 beta. Four studies 
determined a significant association between IL-1b and HCC in HCV- 
infected patients,29-32 whereas two studies investigated the associa-
tion with cirrhosis and fibrosis and found no such association. A total 
of 1226 patients were included in the HCC studies, one study used 
healthy controls,29 two used HCV- infected controls,31,33 and the re-
maining one used controls with HCV- related cirrhosis. Most of these 
studies also assessed or adjusted for differences in factors such as 
HCV genotype and alcohol use.
3.2.11 | MDM2
Three studies were identified for MDM2 (mouse double minute 2 
homolog, a regulator of the p53 tumour suppressor), all using HCC 
as an outcome,5,34,35 with a total of 745 patients. Of the two original 
studies, one found a positive association,5 the one that did not had a 
small sample size and used healthy subjects as the control group. The 
remaining study,35 a meta- analysis, found a significant association in 
the HCV- infected subgroup.
3.2.12 | MICA
There were four individual studies involving the MICA gene (MHC 
class I polypeptide- related sequence A),14,36-38 with a large total 
number of patients included (15 152, although 6880 of these were 
from a single meta- analysis). The study designs are relatively homo-
geneous, with all using HCV- infected patients as the control group. 
All studies found at least one significant association within the MICA 
gene, although some tested multiple SNPs and found associations 
in some but not all of the tested SNPs.36,37 All studies used HCC as 
an outcome and one also found an association with cirrhosis.
3.2.13 | MnSOD
The MnSOD gene encodes the manganese- dependent superoxide dis-
mutase mitochondrial protein. Four relatively small studies (total 755 
patients) investigated the association between HCC and MnSOD.6,7,39,40 
All studies used an HCV- infected comparison population, and three of 
the studies found a significant association.6,39,40 The remaining study 
did not, perhaps due to difference in ethnicities between this and the 
other studies (Caucasian rather than North African).
3.2.14 | PNPLA3
Nine original studies and one meta- analysis studied the PNPLA3 gene 
(patatin- like phospholipase domain- containing protein 3), all inves-
tigating the same SNP, rs738409, in HCV- infected patients. Of the 
three original studies using HCC as an outcome (with a total of 1252 
patients),41-43 two of them found a positive association,41,43 as did 
the meta- analysis.44 The remaining six studies used cirrhosis or fibro-
sis as their outcome and half of these found a significant association, G
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while three did not. This may be due to these studies being per-
formed in a different population (Japanese) than the other studies.
3.2.15 | TGF-­ß1
TGF-ß1 is a gene encoding transforming growth factor beta 1. Six 
studies were identified containing 1356 patients. Of these, just two 
(with 705 patients)45,46 used HCC as an outcome and both of these 
found a significant association using HCV- infected controls. All but 
one of the studies using cirrhosis or fibrosis as an outcome found 
significant associations.
3.2.16 | TNF-­α
The TNF-α gene encodes the tumour necrosis factor alpha cytokine. 
Ten studies studied TNF-α SNPs, with four of them focusing on HCC 
(with 871 patients) and the same TNF-α SNP (rs1800629), and all 
found a similar significant association, despite using a mixture of var-
ious control groups,30,46-48 with one study (Jeng et al) using healthy 
controls. The association was less clear in the studies using cirrhosis 
and fibrosis as outcomes, where only five of nine studied associa-
tions were significant.
3.2.17 | UGT1A7
UDP glucuronosyltransferase 1 family, polypeptide A7, is encoded 
by the UGT1A7 gene. Five of the six studies which focused on 
UGT1A7 used HCC as an outcome,33,49-52 and all but one of these49 
found a significant association. A total of 1450 patients made up 
these studies, and they used a variety of control groups including 
HCV- infected patients and three studies using healthy controls. The 
one study which used cirrhosis as an outcome (and healthy subjects 
as the control) also found a positive association.
3.3 | Studies in need of replication
We identified 37 genes which had a positive association with HCC 
in a single study, but with no confirmatory data from additional 
studies (Table 2 and Appendix S3 available at https://figshare.com/
s/2ffc9030826df2fe150e). However, three of these genes (DHCR7, 
IFN-g, IL-10) had additional evidence of an association with cirrhosis 
or fibrosis. For two studies, a significant association was found for 
multiple SNPs within the same gene (Korner 2012 (DR4), Labib 2015 
(IL-23R)), while four studies investigated multiple SNPs and found only 
one significant association. The median sample size for each individ-
ual study (not including meta- analyses) was 292 (range 75- 5604).
3.4 | Genes/SNPs with some/mixed evidence
A total of 53 genes or gene combinations were classified as having 
some or mixed evidence of an association with HCC, the classifica-
tion being derived from a number of reasons (Table 3 and Appendix 
S3 available at https://figshare.com/s/2ffc9030826df2fe150e). G
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For example some genes, such as FAS, had only studies relating to 
cirrhosis and/or fibrosis. Others, such as CYP2E1, have one study 
finding a positive association with HCC, but then others which 
failed to replicate this association. The total number of patients 
studied for each gene ranged from 30 to 6472 (median 1223), 
while the median sample size for each individual study (not in-
cluding meta- analyses) was 296 (range 30- 6472).
3.5 | Genes/SNPs with only negative studies
There were 27 genes identified where none of the studies 
found a significant association between the gene and liver out-
comes (Table 4 and Appendix S3 available at https://figshare.
com/s/2ffc9030826df2fe150e). All but two of the genes (CYP1A2 
and CYP2R1) had just one study associated with them, although 
some looked at multiple SNPs within the same gene. Seventeen of 
the studies investigated the association with HCC and 13 with cir-
rhosis or fibrosis. The median sample size for each individual study 
(not including meta- analyses) was 262 (range 61- 5604).
4  | DISCUSSION
The most striking features of this review are firstly the wide breadth, 
but disappointingly shallow depth, of the literature on what should 
be a critical area of research, viz. how can studies of host genetics 
TABLE ­4 Genes identified as having been studied for an association with HCC, in patients with HCV, but without any significant 
association found
Gene
HCC
Cirrhosis or 
fibrosisCandidate gene
Positive associations/
number of comparisons
Number of 
papers
Total sample 
size
Comparison group/
baseline population Country/ethnicity
Number of 
papers
A1AT 0/0 0 1
C5 0/0 0 1
CCR5 0/1 1 120 HCV cirrhosis France 0
CD14 0/0 0 1
CIP2A 0/2 1 513 Healthy subjects China 0
COMT 0/1 1 465 HCV infected Caucasian 0
CYP1A1 0/1 1 360 HCV infected Caucasian 0
CYP1A2 0/2 2 848 HCV infected, 
Healthy subjects
Caucasian, Japan 0
CYP2R1 0/1 1 5604 HCV infected Caucasian, Japan 1
CYP3A4 0/1 1 360 HCV infected Caucasian 0
DNMT3B 0/1 1 278 Healthy subjects Morocco 0
H63D 0/0 0 1
HMOX1 0/0 0 1
IFN-L3 0/1 1 1118 HCV infected Taiwan 0
IL-1a 0/0 0 1
IL-1RN 0/0 0 1
IL-4 0/0 0 1
MASP2 0/1 1 263 HCV/HBV coinfected Italy 0
MCP-1 0/1 1 120 HCV cirrhosis France 0
miR-146a 0/1 1 231 HCV infected Chinese 0
MMP-3 0/0 0 1
MTHFR 0/0 0 1
OPN 0/2 1 296 HCV infected Japanese 0
MMP-3 0/0 0  1
MTHFR 0/0 0  1
UGT1A1 0/0 0  1
YKL-40 0/0 0  1
Results for individual studies, including hazard/odds ratios, significance, sample size and inclusion/exclusion criteria can be found in Appendix S3.
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improve stratification and management of patients infected with 
HCV who are at risk of developing HCC. From a search which yielded 
1668 publications, we identified 166 relevant studies measuring as-
sociations with HCC, cirrhosis or fibrosis in HCV- infected patients 
in 137 different genes. Of these, we determined 16 genes and one 
combination of genes with at least some validated evidence of an 
association with HCC, according to a priori criteria, but a large num-
ber of other genes where the evidence is currently insufficient to 
allow conclusions to be drawn; and secondly, the enormous hetero-
geneity in study design and data quality across the different stud-
ies reported in the literature. There was a large variation in study 
size, although this did not appear to vary substantially according to 
whether the genes had a high or low level of evidence. Many of the 
larger studies were GWA studies, which of necessity require a larger 
sample size due to the need for multiple tests for significance. There 
is evidently no agreement on what constitutes an appropriate con-
trol group against which to compare patients with HCV- associated 
HCC with most studies using HCV- infected patients, a smaller num-
ber HCV- infected patients with cirrhosis and a small minority using 
healthy subjects. Our view is that HCV- infected patients with cir-
rhosis but without HCC are the most appropriate control group, and 
therefore, we have highlighted studies of those genes/SNPs with 
the strongest evidence of an association which used that particular 
control group in Table 5. There was also substantial variation in the 
degree of adjustment for confounding factors. Age and sex adjust-
ment was common, and alcohol intake was also used (although it is 
difficult to collect reliable alcohol data). Relatively few studies were 
able to adjust for duration of infection, a critical potential confound-
ing factor relevant to a number of genes. Many studies tested sev-
eral different genes, or SNPs within genes, and found associations in 
some of them. While some studies appropriately adjusted for use of 
multiple comparisons, others did not. Some studies focussed solely 
on HCV- associated HCC, while in others, the HCV- infected patients 
were only a subset of the case group. HBV and HCV–co- infected 
patients also pose a methodological problem. Such studies should be 
interpreted with more caution, as the associations of SNPs with HCC 
may also be mediated through HBV infection.
The criteria for assessment of strength of association of individ-
ual genes/SNPs used in this review are not especially sophisticated, 
being based on the common- sense approach of whether or not indi-
vidual associations have been independently replicated. The scope 
and quality of the literature on this subject is mostly so variable that 
it is not possible to apply any more formal approaches, such as meta- 
analysis, to evaluate the strength of associations. Our approach has, 
nevertheless, highlighted a number of genes/SNPs that will merit 
further analysis in better designed, larger- scale studies addressing 
this clinically relevant issue.
There is a clinical need to identify patients who are at increased 
risk of HCC in a population of HCV- infected patients. Given this, it 
is conceivable that the genes identified as having strong evidence 
of an association could, with appropriate further investigation and 
validation, be combined into a genetic risk score for HCC in HCV- 
infected patients. The cirrhosis risk score 7 (CRS7) aims to do this for T
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cirrhosis and fibrosis,53,54 although we did not find any significant as-
sociations between CRS7 and HCC in our search. Combining a puta-
tive HCC risk score with other clinical data could create a composite 
score with a powerful ability to stratify and predict risk, and thereby 
impact on patient care pathways.
We also identified 37 genes, which had some evidence of an as-
sociation, but without replication in an independent study. These 
genes therefore have potential—but not yet appropriately deter-
mined—utility in a composite score as described above. The 53 genes 
categorized into the some/mixed evidence group are perhaps the 
most heterogeneous in terms of the level of evidence. Some in this 
category only had evidence of association with cirrhosis or fibrosis, 
which may indicate some predisposition to HCC, but further such 
investigation of the direct association is required to conclude this 
with certainty. Other genes had studies with contradictory conclu-
sions, meaning their potential utility as genes defining risk is uncer-
tain. For the 27 genes without any apparent evidence of association 
with HCC, inclusion on this list does not necessarily rule out the pos-
sibility of an association. Equally, it is likely that other genes have 
been studied without finding an association but these data remain 
unpublished.
Due to the number of genes featured in this review, we did not 
attempt to measure the extent of publication bias within the evi-
dence for each gene. It is therefore difficult to know to what extent 
unpublished contradictory evidence might have altered the classifi-
cations made.
Equally, we did not aim to determine any definitive causality 
between the genes identified in this study and the liver disease 
outcomes, taking a utilitarian, not mechanistic approach to the 
data. Some of the described genetic associations may arise from 
direct effects of the SNPs on some aspect of carcinogenesis. 
However, others may arise in the context of potential confounding 
effects, with potential mechanisms other than direct induction of 
HCC. For example, genes such as IFNL3 and IFNL4 are known to 
be associated with treatment response in those treated with inter-
feron regimens.55 For these genes, therefore, the causal mecha-
nism for the association with HCC incidence may be related to the 
duration of infection, rather than any direct effect on liver disease 
progression or hepatocarcinogenesis. The IFNL3/IFNL4 studies 
featured here were broadly not able to adjust for this duration of 
infection. In the new era of DAA treatments, it is possible that 
these associations will cease to exist as response to interferon 
therapy becomes less relevant. Another example of potential con-
founding is PNPLA3, which has previously been linked to alcoholic 
liver disease.56 Although some studies adjusted for alcohol con-
sumption, it is almost certain that at least some of the mechanism 
of association with HCV is due to confounding by alcoholic liver 
disease. These alternative mechanisms do not necessarily detract 
from the gene’s utility as a predictor of HCC, but must be carefully 
considered in any modelling.
We included the evidence surrounding cirrhosis and fibrosis 
within this review as the typical disease course tends to progress 
from fibrosis to cirrhosis and eventually HCC. However, only a small 
percentage of patients who have cirrhosis are likely to get HCC (1%- 
7% per year).2 This means that genes associated with cirrhosis and 
fibrosis do not necessarily translate to risk of HCC as well. It may be 
that different types of genes, such as those involved in cell cycle reg-
ulation, are more likely to be associated with HCC, while other genes 
are likely to be involved in the pathogenesis of fibrosis and cirrhosis.
It is crucial that evidence for each gene should be assessed in 
detail before drawing conclusions as to their utility for risk strati-
fication. This systematic review of the evidence surrounding the 
link between host genetic factors and HCC has produced a signif-
icant aggregation of the evidence available within the literature ad-
dressing this topic. We have identified a number of methodological 
difficulties in studies relating to this issue and the need for a more 
rigorous and systematic approach to identification and validation 
of candidate genes. We have also identified a number of host SNPs 
with at least some validated evidence of an association with HCC in 
HCV- infected patients, which we hope will act as a springboard to 
further studies and the ultimate identification of a clinically useful 
host genetic signature enabling stratification of individual patient 
risk of HCC development.
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